Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026)
Valneva SE's (VALN) quarterly Long-Term Deferred Tax came in at $9.1 million in Q1 2026, up 8.78% year-on-year from $8.4 million in Q1 2025, and down 6.27% quarter-over-quarter from $9.7 million in Q4 2025.
Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Long-Term Deferred Tax across 7 years of filings, most recently posting $9.1 million for Q1 2026.
- Long-Term Deferred Tax for Q1 2026 came in at $9.1 million, up 8.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (up 8.78% YoY), and the FY2025 annual result was $9.7 million, down 5.57% from the prior year.
- Long-Term Deferred Tax came in at $9.1 million for Q1 2026 at Valneva SE, down from $9.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $12.8 million in Q3 2024 to a low of $2.9 million in Q2 2022.
- The 5-year median for Long-Term Deferred Tax is $8.4 million (2025), against an average of $7.7 million.
- Across the five-year window, Long-Term Deferred Tax soared 278.83% in 2023 and slumped 33.04% in 2025, its largest moves.
- Valneva SE's Long-Term Deferred Tax stood at $5.8 million in 2022, then decreased by 11.66% to $5.1 million in 2023, then surged by 102.02% to $10.3 million in 2024, then decreased by 5.57% to $9.7 million in 2025, then declined by 6.27% to $9.1 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $9.1 million (Q1 2026), $9.7 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | 9.69 Mn |
| Sep 30, 2025 | 8.58 Mn |
| Jun 30, 2025 | 9.07 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 10.26 Mn |
| Sep 30, 2024 | 12.81 Mn |
| Jun 30, 2024 | 8.25 Mn |
| Mar 31, 2024 | 7.61 Mn |
| Dec 31, 2023 | 5.08 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 10.82 Mn |
| Mar 31, 2023 | 6.60 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Dec 31, 2020 | 6.64 Mn |